+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RASopathic skin eruptions during vemurafenib therapy

RASopathic skin eruptions during vemurafenib therapy

Plos One 8(3): E58721-E58721

Vemurafenib is a potent inhibitor of V600 mutant BRAF with significant impact on progression-free and overall survival in advanced melanoma. Cutaneous side effects are frequent. This single-center observational study investigates clinical and histological features of these class-specific cutaneous adverse reactions. Patients were all treated with Vemurafenib 960 mg b.i.d. within local ethic committees approved clinical trials. All skin reactions were collected and documented prospectively. Cutaneous reactions were classified by reaction pattern as phototoxic and inflammatory, hair and nail changes, keratinocytic proliferations and melanocytic disorders. Vemurafenib was well tolerated, only in two patients the dose had to be reduced to 720 mg due to arthralgia. 26/28 patients (93%) experienced cutaneous side effects. Observed side effects included UVA dependent photosensitivity (n = 16), maculopapular exanthema (n = 14), pruritus (n = 8), folliculitis (n = 5), burning feet (n = 3), hair thinning (mild alopecia) (n = 8), curly hair (n = 2) and nail changes (n = 2). Keratosis pilaris and acanthopapilloma were common skin reactions (n = 12/n = 13), as well as plantar hyperkeratosis (n = 4), keratoacanthoma (n = 5) and invasive squamous cell carcinoma (n = 4). One patient developed a second primary melanoma after more than 4 months of therapy (BRAF and RAS wild type). Vemurafenib has a broad and peculiar cutaneous side effect profile involving epidermis and adnexa overlapping with the cutaneous manifestations of genetic diseases characterized by activating germ line mutations of RAS (RASopathy). They must be distinguished from allergic drug reaction. Regular skin examination and management by experienced dermatologists as well as continuous prophylactic photo protection including an UVA optimized sun screen is mandatory.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333510

Download citation: RISBibTeXText

PMID: 23516541

DOI: 10.1371/journal.pone.0058721

Related references

RASopathic alopecia: hair changes associated with vemurafenib therapy. Journal of the American Academy of Dermatology 72(4): 738-741, 2015

RASopathic comedo-like or cystic lesions induced by Vemurafenib: A model of skin lesions similar but not identical to those induced by dioxins (MADISH). Journal of the European Academy of Dermatology and Venereology, 2018

Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib. Journal of Dermatology: -, 2016

Acneiform eruptions associated with vemurafenib. Journal of the American Academy of Dermatology 68(3): E97-E99, 2013

Lupus erythematosus-like skin eruption after vemurafenib therapy. Journal of the American Academy of Dermatology 71(4): E159-E160, 2014

Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib. Journal of Clinical and Aesthetic Dermatology 6(5): 27-37, 2013

Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy. Strahlentherapie und Onkologie 190(12): 1169-1172, 2015

Nivolumab therapy before vemurafenib administration induces a severe skin rash. Journal of the European Academy of Dermatology and Venereology, 2016

Acne inversa-like skin lesions as a potential adverse event during vemurafenib therapy. Journal der Deutschen Dermatologischen Gesellschaft 14(4): 427-428, 2016

Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib. Journal of Dermatology: -, 2016

Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. Journal of Clinical Oncology 30(19): E165-E167, 2012

Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. American Journal of Dermatopathology 36(7): 557-561, 2015

BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions. Practical Radiation Oncology 4(5): E213-E216, 2015

Generalized skin eruptions during radiation therapy. Journal of the Maine Medical Association 67(9): 267-74, 274-5, 1976

Steroid preparations for topical therapy of skin eruptions. United States Armed Forces Medical Journal 7(7): 963-978, 1956